* Enliven Therapeutics Announces FDA Alignment on Phase 3 Trial Design for Relcobatinib in Previously Treated Chronic Myeloid Leukemia

(MORE TO FOLLOW) Dow Jones Newswires October 06, 2026 18:12 ET (22:12 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.